Related Experiment Video
Updated: Mar 25, 2026
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Cardiac Hypertrophy and Cardiac Cell Death in Chronic Kidney Disease
Insights
Chronic kidney disease (CKD) causes cardiac hypertrophy but does not induce cardiac cell death, unlike acute myocardial infarction. Caspase-3 activity was reduced in CKD, indicating no apoptosis in cardiac cells.
Area of Science:
- Cardiology
- Nephrology
- Cell Biology
Background:
- Chronic kidney disease (CKD) affects 15% of the population and is linked to cardiorenal syndrome (CRS) type 4, impairing cardiac function.
- The mechanisms connecting CKD to cardiac dysfunction, specifically cardiac cell death, remain unclear.
Purpose of the Study:
- To investigate whether chronic kidney disease (CKD) leads to cardiac cell death through apoptosis.
- To understand the role of apoptosis in the cardiac pathology associated with CKD.
Main Methods:
- Rat models were used for CKD, acute myocardial infarction (MI), left ventricular dysfunction (LVD), and sham procedures.
- Cardiac and kidney hypertrophy were assessed via organ-to-body weight ratios.
- Cardiac cell death was quantified using flow cytometry (annexin-FITC/propidium iodide staining).
- Caspase-3 dependent apoptosis was measured using Western blot analysis.
Main Results:
- CKD, acute MI, and LVD models all demonstrated significant cardiac hypertrophy.
- In contrast to acute MI, CKD did not show increased cardiac cell death.
- Caspase-3 activity was found to be slightly reduced in the CKD group compared to controls.
Conclusions:
- Chronic kidney disease (CKD) induces pathological cardiac changes, including hypertrophy.
- CKD does not appear to mediate cardiac cell death via apoptosis.
- The findings suggest that cardiac dysfunction in CKD may not involve programmed cell death pathways.
Background:
Chronic kidney disease (CKD) is a prevalent clinical condition affecting 15% of the general population. Cardiorenal syndrome (CRS) type 4 is characterized by an underlying CKD condition leading to impairment of cardiac function and increased risk for major cardiovascular events. To date, the mechanisms leading from CKD to CRS are not completely understood. In particular, it is unclear whether the pathological changes that occur in the heart in the setting of CKD involve enhanced cell death of cardiac cells.
Objectives:
To assess whether CKD may mediate loss of cardiac cells by apoptosis.
Methods:
We established rat models for CKD, acute myocardial infarction (acute MI), left ventricular dysfunction (LVD), and sham. We measured the cardiac-to-body weight as well as kidney-to-body weight ratios to validate that renal and cardiac hypertrophy occur as part of disease progression to CRS. Cardiac cells were then isolated and the percent of cell death was determined by flow cytometry following staining with annexin-FITC and propidium iodide. In addition, the levels of caspase-3-dependent apoptosis were determined by Western blot analysis using an anti-cleaved caspase-3 antibody.
Results:
CKD, as well as acute MI and LVD, resulted in significant cardiac hypertrophy. Nevertheless, unlike the increased levels of cell death observed in the acute MI group, in the CKD group, cardiac hypertrophy was not associated with induction of cell death of cardiac cells. Caspase-3 activity was even slightly reduced compared to sham-operated controls.
Conclusions:
Our data show that while CKD induces pathological changes in the heart, it does not induce cardiac cell death.
More Related Videos
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
01:18Chronic Kidney Disease IV: Nursing Management
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:24Chronic Kidney Disease II: Clinical Manifestations
01:28Chronic Kidney Disease III: Interprofessional Care